| Introducing Dr. Tanaz Kermani. | 1.27 |
| Introducing Dr. Peter Merkel. | 2:13 |
| The new ACR / VF Treatment Guidelines. | 4:24 |
| What is ANCA-Associated Vasculitis (AAV) ? | 5:31 |
| Treatment of AAV. | 5:56 |
| Treatment of Non-Severe AAV. | 8:01 |
| Treatment of Severe AAV. | 10:48 |
| Glucocorticoids / Prednisone. | 15:21 |
| Steroid Sparing” in AAV is the goal. | 16:08 |
| The PEXIVAS Trial. | 16:37 |
| What’s better than reduced-dose glucocorticoids? | 19:05 |
| The ADVOCATE Trial. | 20:25 |
| Key points from the ADVOCATE Trial. | 26:10 |
| Who is eligible to receive avocopan? | 26:49 |
| Can I get avocopan if I’m in remission? | 29:03 |
| Is avocopan a replacement for prednisone in all settings? | 29:36 |
| Can I get avocopan if I have a type of vasculitis different from GPA or MPA? | 30:04 |
| Can I switch from azathioprine or methotextrate, or mycophenolate to avocopan? | 30:30 |
| How long should someone stay on avocopan if they go into remission? | 31:02 |
| Should someone who started on rituximab and avacopan who is in remission after six months, be re-treated with rituximab, or keep taking avocopan, or both? | 31:34 |
| What other factors go into the decision to use avocopan to treat GPA, or MPA? | 32:13 |
| Conclusions and Summary. | 32:31 |
| Current random controlled trials in AAV. | 33:15 |
| How can I participate in research on GPA or MPA even if I’m not near a major research center? | 33:36 |
| Q: What are common side effects from avocopan? | 34:38 |
| Q: How is rituximab being used as maintenance therapy? | 35:51 |
| Q: How do patients know if they qualify for Evusheld, and if they are getting it should they also be getting COVID boosters? | 38:02 |
| Q: Is there research into the cause of fatigue and its connection to auto-inflammatory disease? | 40:02 |
| Introductions: Kathy Olevsky, Art Diaz, and Jenn Gordon. | 43:50 |
| Poll question: Do you think your doctor listens to you when you want to discuss different treatments? | 46:27 |
| Discussion: How do you talk to your doctor about a different treatment plan? | 47:38 |
| Discussion: How do you even start the conversation about changing your treatments? | 51:35 |
| Discussion: Do you use electronic records to keep track of your medications and doctor visits. | 55:24 |
Join Dr. Peter Merkel and Dr. Tanaz Kermani for a discussion about current treatments for GPA And MPA, including the recently FDA-approved drug, avacopan. Dr. Merkel gives an overview of the medications and then Dr. Kermani moderates a Q&A session with the attendees.
After the first session we will convene a panel of expert patients, Art Diaz, Jenn Gordon and Kathy Olevsky to discuss “Talking to Your Doctor About Changing Treatments.”
Building upon the collective strength of the vasculitis community, the Foundation supports, inspires and empowers individuals with vasculitis and their families through a wide range of education, research, clinical, and awareness initiatives.
The Vasculitis Foundation is a registered 501 (c) (3) non-profit organization. All contributions are 100% tax-deductible.
Click here to send us an email!
Mail:
Vasculitis Foundation
PO Box 28660
Kansas City, MO 64188
1.816.436.8211 or 1.800.277.9474
All Rights Reserved